Literature DB >> 31818956

Viral neutralization by antibody-imposed physical disruption.

Qingbing Zheng1,2, Jie Jiang1,2, Maozhou He1,2, Zizheng Zheng1,2, Hai Yu1,2, Tingting Li1,2, Wenhui Xue1,2, Zimin Tang1,2, Dong Ying1,2, Zekai Li1,2, Shuo Song1,2, Xinlin Liu1,2, Kaihang Wang1,2, Zhiqing Zhang1,2, Daning Wang1,2, Yingbin Wang1,2, Xiaodong Yan2,3, Qinjian Zhao1,2, Jun Zhang1,2, Ying Gu4,2, Shaowei Li4,2, Ningshao Xia4,2.   

Abstract

In adaptive immunity, organisms produce neutralizing antibodies (nAbs) to eliminate invading pathogens. Here, we explored whether viral neutralization could be attained through the physical disruption of a virus upon nAb binding. We report the neutralization mechanism of a potent nAb 8C11 against the hepatitis E virus (HEV), a nonenveloped positive-sense single-stranded RNA virus associated with abundant acute hepatitis. The 8C11 binding flanks the protrusion spike of the HEV viruslike particles (VLPs) and leads to tremendous physical collision between the antibody and the capsid, dissociating the VLPs into homodimer species within 2 h. Cryo-electron microscopy reconstruction of the dissociation intermediates at an earlier (15-min) stage revealed smeared protrusion spikes and a loss of icosahedral symmetry with the capsid core remaining unchanged. This structural disruption leads to the presence of only a few native HEV virions in the ultracentrifugation pellet and exposes the viral genome. Conceptually, we propose a strategy to raise collision-inducing nAbs against single spike moieties that feature in the context of the entire pathogen at positions where the neighboring space cannot afford to accommodate an antibody. This rationale may facilitate unique vaccine development and antimicrobial antibody design.
Copyright © 2019 the Author(s). Published by PNAS.

Entities:  

Keywords:  antibody; cryo-EM structure; viral neutralization; virus dissociation

Year:  2019        PMID: 31818956     DOI: 10.1073/pnas.1916028116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  4 in total

Review 1.  Antibodies to combat viral infections: development strategies and progress.

Authors:  Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez
Journal:  Nat Rev Drug Discov       Date:  2022-06-20       Impact factor: 112.288

2.  In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.

Authors:  Borris Rosnay Tietcheu Galani; Vincent Brice Ayissi Owona; Romeo Joel Guemmogne Temdie; Karoline Metzger; Marie Atsama Amougou; Pascal Dieudonné Djamen Chuisseu; Arnaud Fondjo Kouam; Marceline Ngounoue Djuidje; Cécile-Marie Aliouat-Denis; Laurence Cocquerel; Paul Fewou Moundipa
Journal:  In Silico Pharmacol       Date:  2021-05-04

Review 3.  Overview of Neutralizing Antibodies and Their Potential in COVID-19.

Authors:  José Javier Morales-Núñez; José Francisco Muñoz-Valle; Paola Carolina Torres-Hernández; Jorge Hernández-Bello
Journal:  Vaccines (Basel)       Date:  2021-11-23

4.  The Capsid (ORF2) Protein of Hepatitis E Virus in Feces Is C-Terminally Truncated.

Authors:  Takashi Nishiyama; Koji Umezawa; Kentaro Yamada; Masaharu Takahashi; Satoshi Kunita; Isao Kii; Hiroaki Okamoto
Journal:  Pathogens       Date:  2021-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.